: We aimed to evaluate
tigecycline on the clinical effectiveness in treating complicated skin and
soft tissue infections (cSSTI), complicated
intra-abdominal infections (cIAI), and
pneumonia, caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, as data are limited. From three medical centers in Taiwan, we retrospectively studied the cSSTI, cIAI, and/or
pneumonia caused by ESBL-producing Enterobacteriaceae. Among the 71 patients, including 39 patients infected with Klebsiella pneumoniae, 30 infected with Escherichia coli and others, the clinical success rate of
tigecycline-based
therapy was 80%-90% for
pneumonia and cSSTI caused by E. coli and 50%-60% for cIAI caused by K. pneumoniae and E. coli. Microbiological and clinical outcome of
pneumonia caused by
carbapenem-resistant K. pneumoniae was poor. Univariate Cox analysis showed that
dyspnea, SOFA score,
septic shock,
thrombocytopenia, prolonged prothrombin time, and lesser microbiological eradication were significant factors associated with 30-day mortality after the end of
therapy. Cox regression proportional hazards model revealed
dyspnea and a SOFA score > 8 to be independently associated with time to death. For ESBL producers,
tigecycline showed good effects for cSSTI and
pneumonia by E. coli, ordinary for cIAI, but ineffective for
pneumonia by K. pneumoniae.
Dyspnea and a high SOFA score predict a poor outcome.